Prostate Cancer
Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-resistant…
The gastroesophageal cancer market (including gastric, gastroesophageal junction, and esophageal cancer) is witnessing a substantial change, largely fueled by the entry of immune checkpoint…
Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, including several targeted and biomarker-driven therapies…
Squamous cell carcinoma of the head and neck (SCCHN)—one of the most commonly diagnosed cancers in China—has a dynamic drug development pipeline, including targeted and biomarker-driven…
Cervical Cancer
Pancreatic Cancer
Breast cancer is the most commonly diagnosed cancer in women in China. The disease has been managed primarily through chemotherapy in China, but several novel, premium-priced targeted therapies—…
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, the treatment of AML in China is…
Epidemiology Data Slicer
Epidemiology Data Slicer
Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-resistant…
EPI Data Slicer
The high incidence, long treatment duration, and multiple lines of therapy in the treatment of breast cancer represent strong commercial opportunity for drug development. The CDK4/6 inhibitors (…
Colorectal cancer is a major public health concern in China and is expected to become the second-most-common cancer in the country by 2031. The treatment of metastatic colorectal cancer is…